source
- Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsScribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.Fierce Biotech · 12d ago↗ source
- BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercomputer for drug R&D, according to the announcement.Fierce Biotech · 12d ago↗ source
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceAfter the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…